A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
Recruiting · NCT05411718 · Registry updated 2026-06-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome | Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Digestive System Diseases, Digestive System Neoplasms, Lynch syndrome, Neoplasms by Site, Nutritional and Metabolic Diseases, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hereditary disease, hereditary neoplastic syndrome, intestinal disorder, metabolic disease, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-06-01 | NCT05411718 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
| National Cancer Institute (NCI) | 3015 |
| National Institutes of Health (NIH) | 667 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| MD Anderson Cancer Center | Houston | United States | 589 |